Tag Archives: NASDAQ:BOLD

Audentes Therapeutics (BOLD) Gets a Hold Rating from Evercore ISI

Evercore ISI analyst Joshua Schimmer maintained a Hold rating on Audentes Therapeutics (BOLD – Research Report) on November 8 and set a price target of $34.00. The company’s shares closed last Monday at $28.57. According to TipRanks.com, Schimmer is a

H.C. Wainwright Reaffirms Their Buy Rating on Audentes Therapeutics (BOLD)

H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Audentes Therapeutics (BOLD – Research Report) today and set a price target of $48.00. The company’s shares closed last Monday at $27.08. According to TipRanks.com, Chattopadhyay ‘s ranking currently consits

Audentes Therapeutics (BOLD) Gets a Buy Rating from Chardan Capital

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Audentes Therapeutics (BOLD – Research Report), with a price target of $50.00. The company’s shares closed last Monday at $27.84. According to TipRanks.com, Amusa is

Audentes Therapeutics (BOLD) Receives a Buy from Chardan Capital

In a report released yesterday, Gbola Amusa from Chardan Capital reiterated a Buy rating on Audentes Therapeutics (BOLD – Research Report), with a price target of $50. The company’s shares closed last Monday at $31.10. According to TipRanks.com, Amusa is

Analysts Offer Insights on Healthcare Companies: Audentes Therapeutics (NASDAQ: BOLD) and Rexahn Pharma (NASDAQ: REXN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Audentes Therapeutics (BOLD – Research Report) and Rexahn Pharma (REXN – Research Report). Audentes Therapeutics (BOLD) Mizuho Securities analyst Difei Yang reiterated a

William Blair Keeps Their Hold Rating on Audentes Therapeutics (BOLD)

William Blair analyst Raju Prasad maintained a Hold rating on Audentes Therapeutics (BOLD – Research Report) yesterday. The company’s shares closed yesterday at $37.03. According to TipRanks.com, Prasad is a 4-star analyst with an average return of 13.6% and a